

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claim 1 (Previously presented): A pharmaceutical composition comprising one compound, wherein the compound is a serotonin reuptake inhibitor, and a second compound, wherein the second compound is a H₃ receptor antagonist, inverse agonist or partial agonist having an affinity for the H₃ receptor below 0.5 μ M.

Claims 2-4 (Canceled)

Claim 5 (Withdrawn): A method of treating depression or an affective disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 1.

Claim 6 (Withdrawn): The method of claim 5, wherein the serotonin reuptake inhibitor is a selective serotonin reuptake inhibitor.

Claim 7 (Withdrawn): The method of claim 5, wherein the H₃ receptor antagonist, inverse agonist or partial agonist is selective for the H₃ receptor.

Claim 8 (Withdrawn): The method of claim 5, wherein the second compound is an antagonist or an inverse agonist at the H₃ receptor.

Claim 9 (Withdrawn): The method of claim 5, wherein the second compound is a H₃ receptor antagonist.

Claim 10 (Withdrawn): The method of claim 5, wherein the serotonin reuptake inhibitor is citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, dapoxetine, duloxetine, vilazodone, nefazodone, imipramine, femoxetine, or clomipramine.

Claim 11 (Withdrawn- currently amended): The method of claim 5, wherein the H₃ receptor H₃ receptor antagonist, inverse agonist or partial agonist is Thioperamide, Ciproxifan, Iodophenpropit, GR 175737, Iodoproxyfan, Proxifan, Perceptin, JB 98064, VUF 9153, A 304121, ~~ABT923~~ ABT239, ABT 834, A 923, A 320436, A 331440, A 349413, A 349821, A 417022, A 423579, A 424835, A 431404, AQ 0145, FUB 181, FUB 360, FUB 407, FUB 637, FUB 836, GR 168320, GSK 189254A, GSK 207040A, GT 2016, GT 2104, GT 2209, GT 2212, GT 2227, GT 2232, GT 2390, GT 2349, GT 2355, GT 2394, Imoproxifan, Impentamine, JNJ 5207852, NNC 0038 0000 1049, NNC 0038 0000 1202, SCH 50971, SCH 79687, UCL 1199, UCL 1283, UCL 1390, UCL 1409, UCL 1860, UCL 1972, UCL 2065, UCL 2138, UCL 2173, UCL 2283, Verongamine, VUF 4163, VUF 5000, or VUF 5182.

Claim 12 (Previously presented): The pharmaceutical composition according to claim 1, further comprising a pharmaceutically acceptable carrier or diluent.

Claim 13 (Previously presented): The pharmaceutical composition according to claim 1, wherein the serotonin reuptake inhibitor is a selective serotonin reuptake inhibitor.

Claim 14 (Previously presented): The pharmaceutical composition according to claim 1, wherein the H₃ antagonist, inverse agonist or partial agonist is selective for the H₃ receptor.

Claim 15 (Previously presented): The pharmaceutical composition according to claim 1, wherein the second compound is a H₃ receptor antagonist.

Claim 16 (Currently amended): The pharmaceutical composition according to claim 1, wherein the serotonin ~~uptake~~ reuptake inhibitor is citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, dapoxetine, duloxetine, vilazodone, nefazodone, imipramine, femoxetine, or clomipramine.

Claim 17 (Currently amended): The pharmaceutical composition according to claim 1, wherein the H₃ antagonist, inverse agonist or partial agonist is Thioperamide, Ciproxifan, Iodophenpropit, GR 175737, Iodoproxyfan, Proxifan, Perceptin, JB 98064, VUF 9153, A 304121, ~~ABT923~~ ABT239, ABT 834, A 923, A 320436, A 331440, A 349413, A 349821, A 417022, A 423579, A 424835, A 431404, AQ 0145, FUB 181, FUB 360, FUB 407, FUB 637, FUB 836, GR 168320, GSK 189254A, GSK 207040A, GT 2016, GT 2104, GT 2209, GT 2212, GT 2227, GT 2232, GT 2390, GT 2349, GT 2355, GT 2394, Imoproxifan, Impentamine, JNJ 5207852, NNC 0038 0000 1049, NNC 0038 0000 1202, SCH 50971, SCH 79687, UCL 1199, UCL 1283, UCL 1390, UCL 1409, UCL 1860, UCL 1972, UCL 2065, UCL 2138, UCL 2173, UCL 2283, Verongamine, VUF 4163, VUF 5000, or VUF 5182.

Claim 18 (Withdrawn- currently amended): The method of claim 5, wherein the serotonin ~~uptake~~ reuptake inhibitor and H₃ antagonist, inverse agonist or partial agonist are administered by simultaneous administration.

Claim 19 (Withdrawn- currently amended): The method of claim 5, wherein the serotonin ~~uptake~~ reuptake inhibitor and H₃ antagonist, inverse agonist or partial agonist are administered in the same unit dosage form.

Claim 20 (Withdrawn- currently amended): The method of claim 5, wherein the serotonin ~~uptake~~ reuptake inhibitor and H₃ antagonist, inverse agonist or partial agonist are administered by sequential administration.

Claim 21 (Withdrawn- currently amended): The method of claim 5, wherein the serotonin ~~uptake~~ reuptake inhibitor and H₃ antagonist, inverse agonist or partial agonist are administered in discrete dosage forms.

Claim 22-34 (Canceled)

Claim 35 (Withdrawn): The method of claim 5, wherein the affective disorder is an anxiety disorder, generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder, social anxiety disorder, an eating disorder, a phobia, dysthymia, premenstrual syndrome, a cognitive disorder, an impulse control disorder, attention deficit hyperactivity disorder, or drug abuse.

Claim 36 (Withdrawn): The method of claim 35, wherein the eating disorder is bulimia, anorexia, or obesity.

Claims 37-42 (Canceled)